Ductal breast carcinoma in situ
MONDO:0005023A carcinoma entirely confined to the mammary ducts. It is also known as DCIS. There is no evidence of invasion of the basement membrane. Currently, it is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis. The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS.
Also known as: DCIS, carcinoma in situ of mammary duct, ductal breast carcinoma in situ, ductal carcinoma in situ, ductal carcinoma in situ (DCIS), ductal carcinoma in situ of breast, ductal carcinoma in situ of the breast, intraductal breast carcinoma
2959 clinical trials for this condition and its sub-types, 152 tagged with Ductal breast carcinoma in situ itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Ductal breast carcinoma in situ
-
New hope for chemo-resistant breast cancer? trial tests immune-boosting drug
Disease control Stopped earlyThis study looked at whether the drug abemaciclib could help people with triple negative breast cancer that didn't respond to standard chemotherapy. The goal was to see if the drug could change the tumor's immune environment to make it more attackable by the body's defenses. The …
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
One-Time radiation during breast surgery: can imaging pick the right patients?
Disease control Stopped earlyThis study looked at whether mammography and breast MRI could help identify patients with early-stage breast cancer (DCIS) who could safely receive a single dose of radiation during surgery, instead of weeks of daily radiation afterward. The goal was to avoid repeat surgeries and…
Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Microscope aims to spare breast cancer patients a second surgery
Diagnosis Stopped earlyResearchers are testing a nonlinear microscope (NLM) that images breast tissue during lumpectomy without the usual slide preparation. The goal is to see if the NLM can help surgeons find close or positive margins right away, so fewer patients need a second operation. The trial en…
Sponsor: Beth Israel Deaconess Medical Center • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
Hot flash relief drug studied in breast cancer patients
Symptom relief Stopped earlyThis study tested fezolinetant, a drug that blocks a brain receptor involved in temperature control, to see if it reduces hot flashes and night sweats in women with breast cancer taking hormone therapy. Nine participants were enrolled before the trial was stopped early. The goal …
Phase 2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Genetic test aims to improve breast cancer decisions for black and hispanic women
Knowledge-focused Stopped earlyThis study looked at whether adding a polygenic risk score (a genetic test) to standard breast cancer risk tools helps African American and Hispanic women make better decisions about screening and prevention. Researchers enrolled 19 women at higher risk for breast cancer. The stu…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Cancer drug tested before surgery for non-invasive breast condition
Knowledge-focused Stopped earlyThis study looked at whether giving the drug palbociclib before surgery could cause changes in breast tissue in people with ductal carcinoma in situ (DCIS), a very early form of breast cancer. It planned to enroll 24 participants, but was stopped early after only 17 joined. The m…
Phase 2 • Sponsor: Georgetown University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC